PF-Atlas › Clinical Trials › NCT07869147

Study of ORJ-001 for the Treatment of IPF

ORJ-001 · Phase 2

Registry ID

NCT07869147

Phase

Phase 2

Status

Recruiting

Drug / intervention

ORJ-001

Sponsor

Oorja Bio, Inc.

Enrollment

Locations

About this trial

ORJ-001 is a new class of drugs intended for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This is a Phase 2 study in two parts; the objective of Part A will determine if ORJ-001 is well-tolerated by patients and how long the drug stays in the body. Part B will test how well the drug affects lung function. Animal models of IPF have shown that ORJ-001 can repair damaged lung tissue and improve markers of lung function.

View NCT07869147 on ClinicalTrials.gov →

Explore related

All ORJ-001 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT07869147 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.